Mayne Pharma GroupASX:MYX +7.53%51 Gross Margin % is 64.89% as of Dec. 2025, which is 24% above its 10-year median of 52.38. GuruFocus rates ASX:MYX with a GF Score™ of 51/100 and a GF Value™ of A$5.31 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 118 Medical Distribution companies, Mayne Pharma Group ranks better than 94.92% on this metric.
The historical rank and industry rank for Mayne Pharma Group's Gross Margin % or its related term are showing as below:
ASX:MYX'
s Gross Margin % Range Over the Past 10 Years
Min: 40.14 Med: 52.38 Max: 62.84
Current: 62.31
During the past 13 years, the highestGross Margin % of Mayne Pharma Group was 62.84%. The lowest was 40.14%. And the median was 52.38%.
ASX:MYX's Gross Margin % is ranked better than 94.92% of 118
companies
in the Medical Distribution industry
Industry Median: 14.975
vs ASX:MYX: 62.31
Mayne Pharma Group had a gross margin of 64.89% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Mayne Pharma Group was 4.60% per year.
Mayne Pharma Group (ASX:MYX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Mayne Pharma Group had a gross margin of 64.89% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Mayne Pharma Group Gross Margin % Related Terms
Mayne Pharma Group Gross Margin % Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MYX vs MCK, COR, CAH: Gross Margin % Comparison
For the Medical Distribution subindustry, Mayne Pharma Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Mayne Pharma Group (ASX:MYX) has a Gross Margin % of 64.89% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Mayne Pharma Group and its competitors. This is 24% above median its historical median of 52.38. Over the past decade, Mayne Pharma Group's Gross Margin % has ranged from 40.14 to 62.84. According to the industry distribution chart, Mayne Pharma Group ranks #6 out of 118 companies in the Medical Distribution industry, placing it in the top 5.1%.
Is Mayne Pharma Group's Gross Margin % too high?
Mayne Pharma Group's current Gross Margin % of 64.89% is 24% above median its 10-year median of 52.38. Over the past 10 years, this metric has ranged from a low of 40.14 to a high of 62.84. The Medical Distribution industry median Gross Margin % is 14.98. Mayne Pharma Group's value of 64.89% is 333.3% above this industry median. Based on the distribution chart, Mayne Pharma Group ranks #6 out of 118 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Gross Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #6 out of 118 companies for Gross Margin %. This places Mayne Pharma Group in the top 5% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 14.98. Mayne Pharma Group's value of 64.89% is 333.3% above this benchmark. Historically, Mayne Pharma Group's own Gross Margin % has ranged from 40.14 to 62.84 over the past decade. While the company's 10-year median is 52.38 vs. the industry median of 14.98, Mayne Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 14.98, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayne Pharma Group's current Gross Margin % of 64.89% is 333.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Gross Margin % is 14.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Gross Margin % is 64.89%, which is 24% above median its own 10-year median of 52.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (ASX:MYX) is currently considered Possible Value Trap. The stock's GF Value™ is A$5.31, compared to a current price of A$2.57 — trading 51.6% below its estimated fair value. The current Gross Margin % is 64.89%, which is 24% above median its 10-year median of 52.38 and 333.3% above the Medical Distribution industry median of 14.98. Mayne Pharma Group's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Mayne Pharma Group (ASX:MYX), the current Gross Margin % is 64.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (ASX:MYX) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of A$2.57 is trading 51.6% below its estimated GF Value™ of A$5.31.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for ASX:MYX:
Gross Margin %: 64.89% (24% above median its 10-year median of 52.38)
GF Value™: A$5.31 vs. price of A$2.57 (51.6% below fair value)
Industry Position: 333.3% above the Medical Distribution median (#6 of 118)
No single metric tells the full story. See the ASX:MYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
51GF Score
Get the complete analysis for ASX:MYX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MYX has been successfully added to your 
